Impact of Bridging Therapy on Infection Incidence and Outcomes Following CAR-T cell Therapy with Axicabtagene Ciloleucel

Mashhood Ur Rehman; Aqeeb Ur Rehman; Fizza Mohsin; Nan Liu; Zuniara Amjad; Haseeba Javed; Amar Samour; Mohammad Osama; Muhammad Yasir; Dr. Muhammad Salman Faisal

doi:10.1016/j.jtct.2025.12.243

February 1, 2026Transplantation and Cellular Therapy

Impact of Bridging Therapy on Infection Incidence and Outcomes Following CAR-T cell Therapy with Axicabtagene Ciloleucel

View at Publisher

Ask AI

Bookmark

Share

Key Points

Bridging therapy significantly reduces infection incidence in patients undergoing CAR-T cell therapy.
Infection rates dropped by 40% in those receiving bridging therapy compared to those who did not.
Observational analysis examines outcomes in cancer patients receiving CAR-T cell therapy with bridging intervention.
Findings indicate that bridging therapy may enhance recovery post CAR-T cell therapy, warranting further exploration.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Observational analysis highlights the effect of bridging therapy on infection rates and clinical outcomes after CAR-T cell therapy with axicabtagene ciloleucel in cancer patients.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Rehman et al. (2026) studied this question.

synapsesocial.com/papers/69a76033c6e9836116a2cb35 https://doi.org/10.1016/j.jtct.2025.12.243

View at Publisher

Ask AI

Bookmark

Share

Impact of Bridging Therapy on Infection Incidence and Outcomes Following CAR-T cell Therapy with Axicabtagene Ciloleucel

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Impact of Bridging Therapy on Infection Incidence and Outcomes Following CAR-T cell Therapy with Axicabtagene Ciloleucel

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Keep reading

Keep reading